Who are APVAC1 vaccine plus Poly-ICLC and GM-CSF's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): aMIL, SK-PC-B70M, IMA901, IO102-IO103, mRNA-1010, PACMx5.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/apvac1-vaccine-plus-poly-iclc-and-gm-csf.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-17 · How we verify

APVAC1 vaccine plus Poly-ICLC and GM-CSF — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

APVAC1 vaccine plus Poly-ICLC and GM-CSF (APVAC1 vaccine plus Poly-ICLC and GM-CSF) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Personalized neoantigen vaccine. Area: Oncology.

phase 1 Personalized neoantigen vaccine Tumor antigens Oncology Small molecule Live · refreshed every 30 min

Target snapshot

APVAC1 vaccine plus Poly-ICLC and GM-CSF (APVAC1 vaccine plus Poly-ICLC and GM-CSF) — Immatics Biotechnologies GmbH. APVAC1 vaccine targets tumor antigens, Poly-ICLC is a Toll-like receptor 3 agonist, and GM-CSF is a granulocyte-macrophage colony-stimulating factor.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
APVAC1 vaccine plus Poly-ICLC and GM-CSF TARGET	APVAC1 vaccine plus Poly-ICLC and GM-CSF	Immatics Biotechnologies GmbH	phase 1	Personalized neoantigen vaccine	Tumor antigens
aMIL	aMIL	Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins	marketed	Personalized neoantigen vaccine	Patient-specific tumor neoantigens
SK-PC-B70M	SK-PC-B70M	SK Chemicals Co., Ltd.	phase 3	Cancer vaccine (personalized neoantigen vaccine)
IMA901	IMA901	Immatics Biotechnologies GmbH	phase 3	Personalized neoantigen vaccine	Patient-specific tumor neoantigens
IO102-IO103	IO102-IO103	IO Biotech	phase 3	Personalized neoantigen vaccine + checkpoint inhibitor combination	Patient-specific neoantigens; CTLA-4
mRNA-1010	mRNA-1010	ModernaTX, Inc.	phase 3	Personalized neoantigen vaccine	Patient-specific tumor neoantigens
PACMx5	PACMx5	SWOG Cancer Research Network	phase 3	Personalized neoantigen vaccine

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Personalized neoantigen vaccine class)

Immatics Biotechnologies GmbH · 2 drugs in this class
ModernaTX, Inc. · 1 drug in this class
SWOG Cancer Research Network · 1 drug in this class
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). APVAC1 vaccine plus Poly-ICLC and GM-CSF — Competitive Intelligence Brief. https://druglandscape.com/ci/apvac1-vaccine-plus-poly-iclc-and-gm-csf. Accessed 2026-05-17.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab